ATOSSA THERAPEUTICS, INC. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Atossa's Board approved a plan to issue one CVR (contingent value right) per share to all shareholders, entitling them to 25% of net proceeds from monetization of the company's first qualifying rare pediatric disease priority review voucher, capped at $50M aggregate. The company holds two FDA rare pediatric disease designations for (Z)-endoxifen but has received no voucher to date; CVRs expire December 31, 2036 unless extended. The CVRs attach to shares and do not trade separately.
Why this rating
CVR is speculative (no voucher awarded yet) but addresses shareholder optionality on uncertain future value. Relative to $107M market cap, potential $50M payment is material if earned, but low probability and contingent nature limit near-term business impact.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.